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F amilial partial lipodystrophy, Dunnigan type (FPLD2; Online Mendelian Inheritance in Man #151660) is a rare, autosomal-dominant disorder caused by heterozygous mutations in the lamin A/C (LMNA) gene on chromosome 1q21-22 (1) (2) (3) (4) (5) . FPLD2 is characterized by gradual loss of subcutaneous (SC) fat from the upper and lower extremities around the time of puberty, with normal fat distribution at birth, infancy, and early childhood (6, 7) . Around the same time, excess fat accumulation has been described to occur in the nonlipodystrophic regions such as the face, neck, dorsocervical, and visceral depots (8) . However, there is a lack of objective data about the precise onset of body fat changes and whether the onset of lipodystrophy is related to puberty or not.
Approximately 500 patients have been reported to have FPLD2, with female predominance (1, 9) . Patients with FPLD2, especially adult women, can develop severe metabolic abnormalities related to insulin resistance such as hypertriglyceridemia, diabetes mellitus, hepatic steatosis, polycystic ovarian syndrome, and premature atherosclerosis (9) (10) (11) (12) . However, the onset and severity of metabolic complications in children harboring FPLD2-causing LMNA mutations remains unknown. Therefore, in this retrospective, observational study, we assessed regional body fat distribution and metabolic parameters in children with FPLD2-causing LMNA mutations to understand the time of onset of lipodystrophy and metabolic complications. We also evaluated the diagnostic predictability of various anthropometric parameters, including skinfold thickness measurements by calipers and regional body fat assessment by dualenergy X-ray absorptiometry (DEXA) for FPLD2 in children.
Subjects and Methods

Subjects
We conducted a retrospective cross-sectional survey of phenotypic and metabolic changes in children #18 years of age harboring FPLD2-causing LMNA mutations referred to UT Southwestern Medical Center from 1990 to 2017. The study protocol was approved by the Institutional Review Boards of the UT Southwestern Medical Center and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. All patients and/or legal guardians gave written informed consent. Two patients were recruited at the National Institutes of Health and genotyped at UT Southwestern Medical Center. The children were either probands or ascertained from families with an adult proband having FPLD2 and confirmed to have the disease-causing LMNA variant. We also analyzed longitudinal data on two children who were followed for a period of 3 and 10 years, respectively. Data from sex-and age-matched controls from the National Health and Nutrition Examination Survey (NHANES) 2005 to 2010 were used for comparison (https:// www.cdc.gov/nchs/nhanes/index.htm).
Methods
Questionnaire
Demographic data and health history were reported by the children or their parents either during physician interview or using the lipodystrophy questionnaire.
Anthropometric measurements
Height and body weight were measured with standard procedures. Skinfold thickness was measured with a Lange caliper (Cambridge Scientific Industries, Cambridge, MD) at the chin and five truncal (chest, midaxillary, abdominal, subscapular, and suprailiac) and four peripheral (biceps, triceps, thigh, and calf) sites on the right side of the body. The mean of three repeat measurements at each site was calculated. For comparison, only the subscapular and triceps skinfold thickness measurements were available from the NHANES database.
Laboratory results
Blood was collected after overnight fast for serum lipoproteins and glucose.
Mutational analyses
The LMNA exons including the splice site regions were amplified in 11 segments from 50 ng of genomic DNA using the PCR and exon-specific primer pairs (available on request). The resulting PCR product was analyzed in an agarose gel and purified using a PCR purification kit (Qiagen, Valencia, CA). The purified PCR products were sequenced using dye-terminator chemistry and an ABI 3730xl DNA analyzer (Applied Biosystems, Foster City, CA). Sequence variants were verified by manually inspecting the chromatograms of both the wild-type and mutated products.
DEXA
Whole-body, trunk, upper limb, and lower limb fat mass measurements were obtained by DEXA scan using Discovery W (S/N 80502) model machine (Hologic Inc., Bedford, MA) in children 8 to 18 years of age. Mean values of the right and left upper and lower limbs (percentage of regional fat) were calculated.
Statistical Analysis
The data for females and males were analyzed separately. To estimate NHANES percentiles for metabolic, skinfold thickness, and DEXA variables, the appropriate complex survey design sample weights were taken into account because of the unequal probabilities for selection as described on the NHANES website. Comparison of measurements of children with FPLD2-causing LMNA mutations to the corresponding sex and age group NHANES median value was made with the one-sample Wilcoxon signed-rank test. The association between serum triglycerides and skinfold measurements was analyzed with Spearman rank correlation analysis. All analyses were performed using SAS software version 9.4 (SAS Institute, Inc., Cary, NC). A two-sided P value ,0.05 was the criterion for statistical significance.
Results
We identified a total of 46 children: 32 females (age range 3 to 18 years; median age 15 years) and 14 males (age range 1 to 18 years; median age 10.5 years), with FPLD2-causing LMNA mutations. Six out of 32 females (age range 14 to 18 years) were probands, and the other 26 females and 14 males were ascertained from families with an adult proband having FPLD2. Sixty-three percent of the subjects were white, 26% were Hispanic, 4.5% were Asian, 2.2% were Native Americans, 2.2% were Native Hawaiian, and 2% were unknown. All of these children had disease-causing, missense LMNA mutations. The heterozygous p.R482W, p.R482Q, and p.R482L LMNA mutations, which are associated with the "typical" FPLD2 in the adults (7), were present in 23, 10, and 2 children, respectively. The other "atypical" heterozygous LMNA mutations were p.R582S (n = 2), p.R582H (n = 1), p.S583L (n = 2), p.R28W (n = 1), p.R25L (n = 1), p.G465D (n = 1), p.K486N (n = 1), and p.K515E (n = 1). One patient had a homozygous p.R582H mutation. Seventy-eight percent of females and 71% of males had typical FPLD2-causing LMNA mutations. Historically, adults with FPLD2 harboring typical LMNA mutations, especially females, have been reported to have severe loss of SC fat from the extremities and develop moderate to severe metabolic complications (9, 13) . In contrast, adults with FPLD2 harboring atypical LMNA mutations have variable loss of SC fat from the extremities and mild to severe metabolic complications (7, 14) .
Comparison of skinfold thickness of female and male children with FPLD2 to sex-and age-matched controls from NHANES 2005 to 2010 is shown in Fig. 1 . All affected females with typical LMNA mutations had triceps skinfold thickness values ,25th percentile of NHANES, with many having values ,1st percentile, especially those .16 years of age. Two of them aged eight years had triceps skinfold thickness values below the first percentile. The subscapular skinfold thickness values in female children with FPLD2, in contrast, were between the 5th to 95th percentiles of NHANES and showed a trend toward higher values with increasing age (14 to 18 years). The male FPLD2 children had triceps skinfold thickness values between the 1st and 75th percentile and subscapular skin fold thickness values in the 5th to 95th percentile. We categorized the affected subjects into three age groups (0 to 6 years, 7 to 12 years, and 13 to 18 years) for further comparison with their sex-and age-matched controls from the NHANES (Tables 1 and 2 ). The triceps skinfold thicknesses of the affected females aged 13 to 18 years (median 5.4 mm) were significantly decreased compared with the NHANES data (median 17.8 mm; P = 0.002). In contrast, subscapular skinfold thicknesses in the affected females from aged 13 to 18 years were significantly increased (median 18.3 mm) compared with NHANES (median 13.1 mm; P = 0.03). The triceps skinfold thicknesses of the affected males aged 13 to 18 years were decreased (median 6.5 mm) compared with the NHANES data (median 10.5 mm), and subscapular skinfold thickness increased (median 11.5 mm) compared with the NHANES data (median 9.6 mm), but the differences were not statistically significant (both P = 0.5).
Longitudinal skinfold thickness measurements over a period of 10 years in a female with a typical LMNA mutation (p.R482W) (Fig. 2) show that the triceps skinfold thickness was already at about the first percentile at age 8 years, much before the time of thelarche, at age 9.5 years (Fig. 3 ). Her lower extremities had a muscular appearance at the age of 6 years ( Fig. 2) , with her thigh skinfold thickness value of 10.5 mm (much below the 10th percentile value of 13 mm in prepubertal girls, aged 4 to 10 years) (15, 16) . The mean values of truncal skinfolds (subscapular, chest, axilla, suprascapular, and abdominal skinfolds) and peripheral skinfolds (biceps, triceps, thigh, and calf skinfolds) in this patient revealed that fat loss in the periphery started before 8 years of age and excessive fat deposition in the chin began at ;11 years of age (Fig. 3) .
Regional body fat measurements by DEXA in the affected subjects are shown in Fig. 4 . All affected females, except one with atypical FPLD2 (p.R25L mutation), had lower limb fat at or below the first percentile of NHANES after 8 years of age. Interestingly, of the few affected males, two with typical FPLD2 had lower limb fat ,5th percentile of NHANES and the two with atypical FPLD2 had lower limb fat ,25th percentile of NHANES. Longitudinal DEXA scans in the female with typical LMNA mutation (p.R482W) (Fig. 4) further confirm that the extremity fat loss was already marked before thelarche. Table 1 shows that the upper and lower limb percent fat values in females aged 13 to 18 years were significantly decreased when compared with NHANES controls (both P = 0.004). In contrast, upper and lower limb percent fat values in males aged 13 to 18 years were lower, but results were not statistically significant when compared with the NHANES controls (both P = 0.5) ( Table 2) . Fasting serum triglycerides levels in the affected females were significantly increased as compared with the NHANES data for ages 7 to 12 years (median 123 mg/dL vs 68 mg/dL, respectively; P = 0.05) and ages 13 to 18 years (287 mg/dL vs 71 mg/dL, respectively; P , 0.0001) ( Table 1 ; Fig. 5 ). Also, serum high-density lipoprotein (HDL) cholesterol levels in the affected females were significantly lower, as compared with the NHANES data, for the age group 13 to 18 years (median 33.5 mg/dL vs 53.5 mg/dL, respectively; P = 0.0003), but not in age group 7 to 12 years. Interestingly, fasting serum glucose levels in 13-year-old to 18-year-old affected females were significantly lower than the NHANES data (median 85 mg/dL vs 91 mg/dL, respectively; P = 0.02), but were not different in the other two age groups. No subject with typical FPLD2 and only one girl with atypical FPLD2 (heterozygous for p.K486N variant) developed diabetes mellitus before 18 years of age.
In contrast, metabolic variables for the affected males were not significantly different than the NHANES data in any age group. For ages 13 to 18 years, median fasting serum triglycerides levels were 90.5 mg/dL in the affected males vs 71 mg/dL in the controls (P = 0.44); median serum HDL cholesterol levels were 35.7 mg/dL in the affected males vs 48.8 mg/dL in the controls (P = 0.13); and median serum glucose levels were 89 mg/dL vs 95 mg/dL, respectively (P = 0.06) ( Table 2 ; Fig. 5 ).
Among females with FPLD2-causing LMNA mutations, we observed a strong inverse correlation between fasting serum triglycerides levels and triceps skinfold thickness (Spearman r = 20.82; P = 0.0001) and thigh skinfold thickness (r = 20.71; P = 0.004) measurements (Fig. 6) . No relationship, however, was observed between fasting serum triglycerides levels and subscapular skinfold thickness (r = 20.005; P = 0.98) (Fig. 6) .
Discussion
No previous studies have systematically evaluated body fat distribution in children harboring FPLD2-causing LMNA mutations. Thus, the precise time of onset of lipodystrophy as well as excess fat accumulation in nonlipodystrophic regions in FPLD2 and whether these changes are related to the onset of puberty remain unknown. Our cross-sectional data, especially in female children with FPLD2, reveal that marked loss of SC fat from the extremities occurs much before the pubertal age (mean age of thelarche and menarche is 10.2 and 12.6 years, respectively, in normal US population) (17). The triceps skinfold thickness data reveal markedly low values (below the first percentile of NHANES) in two females and in two boys aged 8 to 11 years, suggesting prepubertal onset of lipodystrophy. Furthermore, the lower limb fat (percentage) from DEXA scans showed markedly low values (below the 1st percentile in many girls younger than age 12 and in one boy at age 8 years). Thus, we conclude that the onset of lipodystrophy in children harboring FPLD2-causing LMNA mutations occurs much before puberty. This contention is further supported by the longitudinal data from age 6 to 16 years in a female with typical FPLD2. She not only showed objective evidence of partial lipodystrophy affecting mainly the lower extremities at age 6 years with marked muscular appearance but also had triceps skinfold thickness and lower limb fat values below the first percentiles of NHANES much before the onset of thelarche. Interestingly, her longitudinal data further reveal that the accumulation of SC fat in the chin region actually started around age 12 years, 2 years after the onset of menarche.
Despite the fact that our study reports anthropometric and metabolic data on the largest cohort of children carrying FPLD2-causing LMNA mutations, because the data from males were limited to only 14 subjects in our study, the comparisons with the NHANES data may not have had sufficient power for detecting marked differences. Measures of regional body fat by DEXA show that all affected females .12 years of age have lower limb fat below the first percentile of the NHANES data. However, males did not have considerable SC fat loss until 18 years of age. This is in contrast to adult males and females with FPLD2, both of whom have been shown to have similar patterns of fat loss (9) .
Our data also support the diagnostic value of DEXAderived lower limb fat (percentage) below the first percentile of NHANES control data in female children (8 to 18 years old) with FPLD2, more so than the triceps skinfold thickness measurement. Although the thigh skinfold thickness could be more predictive than the triceps skinfold thickness, unfortunately, for lack of data on thigh skinfold thickness from NHANES or any other database, we were not able to evaluate its predictability.
Fasting serum triglycerides were significantly elevated and HDL-cholesterol levels were significantly lower in the affected females 12 to 18 years of age compared with the NHANES controls. Males, however, did not show any remarkable metabolic changes until 18 years of age. These results are consistent with previous reports describing more severe metabolic complications in adult females with FPLD2 when compared with males (9, 13) . Another recent retrospective study reported three affected females and four affected males (age range 1 to 18 years) from Turkey, of whom only one 18-year-old male had hypertriglyceridemia, and another 18-year-old female had hypertriglyceridemia and impaired glucose tolerance (18) .
Our cohort showed female predominance, with a female/male ratio of 2.5:1 despite an autosomal-dominant inheritance pattern with an expected female-to-male ratio of 1:1. We believe that the female preponderance is mainly due to easier recognition of the clinical phenotype in them. For example, 18% of the females (age range 14 to 18 years) were probands, whereas no male probands presented before 18 years of age. A recent study described 85 patients with FPLD2 (26 males and 59 females) from 24 families with FPLD2 over three generations, and the female-to-male ratio was 29:10 in the first generation, 25:16 in the second generation, and 5:0 in the third generation (19) . However, they included only patients with disease-causing LMNA mutations along with lipodystrophy, diabetes, or hypertriglyceridemia, which might explain the female predominance (19) . Unlike the generalized forms of lipodystrophy, partial lipodystrophies can present with subtle and variable phenotype and metabolic profiles, which makes the diagnosis of FPLD2 very challenging, and particularly so in males, because many normal young males are also muscular and have reduced SC fat in the extremities. We conclude that cascade screening, a mechanism for identifying people at risk for a genetic condition by a process of systematic family tracing (20, 21) , is needed to identify asymptomatic affected males carrying FPLD2-causing LMNA mutations.
Loss of SC fat from the triceps and thigh regions as measured by skinfold thickness in affected females had a very strong inverse relationship with serum triglyceride levels, and this can act as a sensitive marker for metabolic derangements in patients with FPLD2. Interestingly, subscapular skinfold thickness had no relationship with serum triglycerides. Specific mechanisms by which LMNA mutations cause fat loss and metabolic complications still remain to be elucidated. Longitudinal studies looking into body composition, sex hormones, metabolic variables, and adipose tissue gene expression are needed to shed more light into pathophysiology of FPLD2.
We conclude that the onset of extremity fat loss in children, especially in females, with FPLD2-causing LMNA mutations occurs much before the onset of puberty. There is marked phenotypic heterogeneity among children harboring FPLD2-causing LMNA mutations, with some postpubertal children presenting with FPLD2 and metabolic complications, whereas younger children may not develop metabolic complications. Finally, the severity of fat loss from the extremities may determine elevation of serum triglycerides among female children with FPLD2.
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